Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Peter Thomas Lansbury, Ph.D.

Title
Institution
Department
Address
Phone
Fax

Mentoring
Cell System Characterization of a Dopamine-æ-Synuclein Adduct Implicated in Parkinson's Disease
Summer, 06/17/02 - 08/23/02

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R21NS053749 (LANSBURY, PETER T) Sep 30, 2005 - Aug 31, 2006
    NIH
    A High-Throughput Assay-SOD1 Aggregation Inhibitors(RMI)
    Role: Principal Investigator
  2. R03NS051243 (LANSBURY, PETER T) Apr 1, 2005 - Mar 31, 2007
    NIH
    Discovery of highly toxic synuclein sequence variants
    Role: Principal Investigator
  3. R21NS047420 (LANSBURY, PETER T) Jul 1, 2004 - Jun 30, 2006
    NIH
    High Throughout Assay to Probe UCH-L1 Ligase Inhibitors
    Role: Principal Investigator
  4. P50NS038375 (LANSBURY, PETER T) Sep 30, 1999 - Aug 31, 2011
    NIH
    Familial Parkinson's Disease: Clues to Pathogenesis
    Role: Principal Investigator
  5. P01AG014366 (LANSBURY, PETER T) Jun 1, 1997 - May 31, 2003
    NIH
    ALZHEIMER AMYLOIDOGENESIS WITH NEW METHODS
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Lansbury P. The Jury Is Still Out. Mov Disord. 2022 03; 37(3):651. PMID: 35040206.
    Citations:    Fields:    Translation:Humans
  2. Oliveira LMA, Gasser T, Edwards R, Zweckstetter M, Melki R, Stefanis L, Lashuel HA, Sulzer D, Vekrellis K, Halliday GM, Tomlinson JJ, Schlossmacher M, Jensen PH, Schulze-Hentrich J, Riess O, Hirst WD, El-Agnaf O, Mollenhauer B, Lansbury P, Outeiro TF. Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. NPJ Parkinsons Dis. 2021 Jul 26; 7(1):65. PMID: 34312398.
    Citations: 11     
  3. den Heijer JM, Kruithof AC, van Amerongen G, de Kam ML, Thijssen E, Grievink HW, Moerland M, Walker M, Been K, Skerlj R, Justman C, Dudgeon L, Lansbury P, Cullen VC, Hilt DC, Groeneveld GJ. A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator. Br J Clin Pharmacol. 2021 09; 87(9):3561-3573. PMID: 33576113.
    Citations: 5     Fields:    Translation:Humans
  4. den Heijer JM, Schmitz A, Lansbury P, Cullen VC, Hilt DC, Bonifati V, Groeneveld GJ. False negatives in GBA1 sequencing due to polymerase dependent allelic imbalance. Sci Rep. 2021 01 08; 11(1):161. PMID: 33420335.
    Citations: 1     Fields:    Translation:Humans
  5. Caputo S, Di Martino S, Cilibrasi V, Tardia P, Mazzonna M, Russo D, Penna I, Summa M, Bertozzi SM, Realini N, Margaroli N, Migliore M, Ottonello G, Liu M, Lansbury P, Armirotti A, Bertorelli R, Ray SS, Skerlj R, Scarpelli R. Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors. J Med Chem. 2020 12 24; 63(24):15821-15851. PMID: 33290061.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  6. den Heijer JM, Cullen VC, Quadri M, Schmitz A, Hilt DC, Lansbury P, Berendse HW, van de Berg WDJ, de Bie RMA, Boertien JM, Boon AJW, Contarino MF, van Hilten JJ, Hoff JI, van Mierlo T, Munts AG, van der Plas AA, Ponsen MM, Baas F, Majoor-Krakauer D, Bonifati V, van Laar T, Groeneveld GJ. A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands. Mov Disord. 2020 09; 35(9):1667-1674. PMID: 32618053.
    Citations: 10     Fields:    Translation:Humans
  7. Di Martino S, Tardia P, Cilibrasi V, Caputo S, Mazzonna M, Russo D, Penna I, Realini N, Margaroli N, Migliore M, Pizzirani D, Ottonello G, Bertozzi SM, Armirotti A, Nguyen D, Sun Y, Bongarzone ER, Lansbury P, Liu M, Skerlj R, Scarpelli R. Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors. J Med Chem. 2020 04 09; 63(7):3634-3664. PMID: 32176488.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  8. Cuddy LK, Wani WY, Morella ML, Pitcairn C, Tsutsumi K, Fredriksen K, Justman CJ, Grammatopoulos TN, Belur NR, Zunke F, Subramanian A, Affaneh A, Lansbury PT, Mazzulli JR. Stress-Induced Cellular Clearance Is Mediated by the SNARE Protein ykt6 and Disrupted by a-Synuclein. Neuron. 2019 12 04; 104(5):869-884.e11. PMID: 31648898.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  9. Zheng J, Chen L, Skinner OS, Ysselstein D, Remis J, Lansbury P, Skerlj R, Mrosek M, Heunisch U, Krapp S, Charrow J, Schwake M, Kelleher NL, Silverman RB, Krainc D. ß-Glucocerebrosidase Modulators Promote Dimerization of ß-Glucocerebrosidase and Reveal an Allosteric Binding Site. J Am Chem Soc. 2018 05 09; 140(18):5914-5924. PMID: 29676907; PMCID: PMC6098685.
    Citations: 8     Fields:    Translation:HumansCells
  10. Collier TJ, Srivastava KR, Justman C, Grammatopoulous T, Hutter-Paier B, Prokesch M, Havas D, Rochet JC, Liu F, Jock K, de Oliveira P, Stirtz GL, Dettmer U, Sortwell CE, Feany MB, Lansbury P, Lapidus L, Paumier KL. Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. Neurobiol Dis. 2017 Oct; 106:191-204. PMID: 28711409; PMCID: PMC5793922.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  11. Vamvaca K, Lansbury PT, Stefanis L. N-terminal deletion does not affect a-synuclein membrane binding, self-association and toxicity in human neuroblastoma cells, unlike yeast. J Neurochem. 2011 Oct; 119(2):389-97. PMID: 21848810.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  12. Nowak RJ, Cuny GD, Choi S, Lansbury PT, Ray SS. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. J Med Chem. 2010 Apr 08; 53(7):2709-18. PMID: 20232802; PMCID: PMC2881568.
    Citations: 16     Fields:    Translation:HumansCells
  13. Vamvaca K, Volles MJ, Lansbury PT. The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J Mol Biol. 2009 Jun 05; 389(2):413-24. PMID: 19285989.
    Citations: 50     Fields:    Translation:AnimalsCells
  14. Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, Liu Y, Logan T, Lansbury PT. Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci U S A. 2009 Mar 24; 106(12):4635-40. PMID: 19261853.
    Citations: 68     Fields:    Translation:HumansAnimalsCells
  15. Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PT, Fernandez CO, Eliezer D, Zweckstetter M, Lashuel HA. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem. 2008 Jun 13; 283(24):16895-905. PMID: 18343814.
    Citations: 153     Fields:    Translation:HumansCells
  16. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, Hodara R, Fredenburg R, Wu DC, Follenzi A, Dauer W, Przedborski S, Ischiropoulos H, Lansbury PT, Sulzer D, Cuervo AM. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest. 2008 Feb; 118(2):777-88. PMID: 18172548; PMCID: PMC2157565.
    Citations: 303     Fields:    Translation:AnimalsCells
  17. Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, Eliezer D, Lansbury PT. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry. 2007 Jun 19; 46(24):7107-18. PMID: 17530780.
    Citations: 105     Fields:    Translation:HumansCells
  18. Meray RK, Lansbury PT. Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1. J Biol Chem. 2007 Apr 06; 282(14):10567-75. PMID: 17259170.
    Citations: 37     Fields:    Translation:HumansAnimalsCells
  19. Follmer C, Romão L, Einsiedler CM, Porto TC, Lara FA, Moncores M, Weissmüller G, Lashuel HA, Lansbury P, Neto VM, Silva JL, Foguel D. Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein. Biochemistry. 2007 Jan 16; 46(2):472-82. PMID: 17209557.
    Citations: 15     Fields:    Translation:HumansCells
  20. Volles MJ, Lansbury PT. Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol. 2007 Mar 09; 366(5):1510-22. PMID: 17222866; PMCID: PMC1868670.
    Citations: 80     Fields:    Translation:HumansAnimalsCells
  21. Luchansky SJ, Lansbury PT, Stein RL. Substrate recognition and catalysis by UCH-L1. Biochemistry. 2006 Dec 12; 45(49):14717-25. PMID: 17144664.
    Citations: 13     Fields:    Translation:HumansCells
  22. Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature. 2006 Oct 19; 443(7113):774-9. PMID: 17051203.
    Citations: 215     Fields:    Translation:HumansAnimalsCells
  23. Lashuel HA, Lansbury PT. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys. 2006 May; 39(2):167-201. PMID: 16978447.
    Citations: 146     Fields:    Translation:HumansCells
  24. Lansbury PT. Improving synaptic function in a mouse model of AD. Cell. 2006 Aug 25; 126(4):655-7. PMID: 16923386.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  25. Das C, Hoang QQ, Kreinbring CA, Luchansky SJ, Meray RK, Ray SS, Lansbury PT, Ringe D, Petsko GA. Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. Proc Natl Acad Sci U S A. 2006 Mar 21; 103(12):4675-80. PMID: 16537382; PMCID: PMC1450230.
    Citations: 79     Fields:    Translation:HumansCells
  26. Volles MJ, Lansbury PT. A computer program for the estimation of protein and nucleic acid sequence diversity in random point mutagenesis libraries. Nucleic Acids Res. 2005; 33(11):3667-77. PMID: 15990391; PMCID: PMC1166583.
    Citations: 6     Fields:    
  27. Ray SS, Nowak RJ, Brown RH, Lansbury PT. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc Natl Acad Sci U S A. 2005 Mar 08; 102(10):3639-44. PMID: 15738401; PMCID: PMC553303.
    Citations: 52     Fields:    Translation:HumansCells
  28. Lansbury PT, Fagan T. Your health in the 21st century. A fix for faulty proteins. Newsweek. 2005; 145(26A):52. PMID: 16375147.
    Citations:    Fields:    Translation:HumansCells
  29. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004 Aug 27; 305(5688):1292-5. PMID: 15333840.
    Citations: 828     Fields:    Translation:AnimalsCells
  30. Lansbury PT. Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. Nat Med. 2004 Jul; 10 Suppl:S51-7. PMID: 15298008.
    Citations: 27     Fields:    Translation:HumansAnimals
  31. Ray SS, Nowak RJ, Strokovich K, Brown RH, Walz T, Lansbury PT. An intersubunit disulfide bond prevents in vitro aggregation of a superoxide dismutase-1 mutant linked to familial amytrophic lateral sclerosis. Biochemistry. 2004 May 04; 43(17):4899-905. PMID: 15109247.
    Citations: 52     Fields:    Translation:HumansCells
  32. Ray SS, Lansbury PT. A possible therapeutic target for Lou Gehrig's disease. Proc Natl Acad Sci U S A. 2004 Apr 20; 101(16):5701-2. PMID: 15079068; PMCID: PMC395856.
    Citations: 12     Fields:    Translation:HumansCells
  33. Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, Bieganski RM, Lindquist SL, Lansbury PT. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci. 2004; 23(1-2):23-34. PMID: 15126689.
    Citations: 70     Fields:    Translation:HumansAnimalsCells
  34. Kheterpal I, Lashuel HA, Hartley DM, Walz T, Lansbury PT, Wetzel R. Abeta protofibrils possess a stable core structure resistant to hydrogen exchange. Biochemistry. 2003 Dec 09; 42(48):14092-8. PMID: 14640676.
    Citations: 35     Fields:    Translation:HumansCells
  35. Lashuel HA, Hartley DM, Petre BM, Wall JS, Simon MN, Walz T, Lansbury PT. Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol. 2003 Sep 26; 332(4):795-808. PMID: 12972252.
    Citations: 73     Fields:    Translation:HumansAnimalsCells
  36. Liu Y, Lashuel HA, Choi S, Xing X, Case A, Ni J, Yeh LA, Cuny GD, Stein RL, Lansbury PT. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol. 2003 Sep; 10(9):837-46. PMID: 14522054.
    Citations: 98     Fields:    Translation:HumansCells
  37. Foguel D, Suarez MC, Ferrão-Gonzales AD, Porto TC, Palmieri L, Einsiedler CM, Andrade LR, Lashuel HA, Lansbury PT, Kelly JW, Silva JL. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9831-6. PMID: 12900507; PMCID: PMC187855.
    Citations: 43     Fields:    Translation:Humans
  38. Volles MJ, Lansbury PT. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry. 2003 Jul 08; 42(26):7871-8. PMID: 12834338.
    Citations: 126     Fields:    Translation:HumansAnimalsCells
  39. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003; 26:267-98. PMID: 12704221.
    Citations: 553     Fields:    Translation:HumansAnimalsCells
  40. Park JY, Lansbury PT. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry. 2003 Apr 08; 42(13):3696-700. PMID: 12667059.
    Citations: 58     Fields:    Translation:HumansCells
  41. Kessler JC, Rochet JC, Lansbury PT. The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation. Biochemistry. 2003 Jan 28; 42(3):672-8. PMID: 12534279.
    Citations: 49     Fields:    Translation:HumansCells
  42. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell. 2002 Oct 18; 111(2):209-18. PMID: 12408865.
    Citations: 241     Fields:    Translation:HumansAnimalsCells
  43. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol. 2002 Oct 04; 322(5):1089-102. PMID: 12367530.
    Citations: 263     Fields:    Translation:HumansAnimalsCells
  44. Lansbury PT, Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr Opin Cell Biol. 2002 Oct; 14(5):653-60. PMID: 12231362.
    Citations: 19     Fields:    Translation:Humans
  45. Anguiano M, Nowak RJ, Lansbury PT. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry. 2002 Sep 24; 41(38):11338-43. PMID: 12234175.
    Citations: 107     Fields:    Translation:HumansCells
  46. Ding TT, Lee SJ, Rochet JC, Lansbury PT. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry. 2002 Aug 13; 41(32):10209-17. PMID: 12162735.
    Citations: 122     Fields:    Translation:HumansAnimalsCells
  47. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 2002 Jul 18; 418(6895):291. PMID: 12124613.
    Citations: 439     Fields:    Translation:HumansCells
  48. Lansbury PT, Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr Opin Genet Dev. 2002 Jun; 12(3):299-306. PMID: 12076673.
    Citations: 15     Fields:    Translation:HumansCells
  49. Volles MJ, Lansbury PT. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry. 2002 Apr 09; 41(14):4595-602. PMID: 11926821.
    Citations: 162     Fields:    Translation:HumansAnimalsCells
  50. Shtilerman MD, Ding TT, Lansbury PT. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry. 2002 Mar 26; 41(12):3855-60. PMID: 11900526.
    Citations: 89     Fields:    Translation:HumansCells
  51. Conway KA, Rochet JC, Bieganski RM, Lansbury PT. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 2001 Nov 09; 294(5545):1346-9. PMID: 11701929.
    Citations: 357     Fields:    Translation:HumansAnimalsCells
  52. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry. 2001 Jul 03; 40(26):7812-9. PMID: 11425308.
    Citations: 220     Fields:    Translation:HumansCells
  53. Lansbury PT. Following nature's anti-amyloid strategy. Nat Biotechnol. 2001 Feb; 19(2):112-3. PMID: 11175720.
    Citations: 4     Fields:    Translation:HumansCells
  54. Rochet JC, Conway KA, Lansbury PT. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry. 2000 Sep 05; 39(35):10619-26. PMID: 10978144.
    Citations: 72     Fields:    Translation:HumansAnimalsCells
  55. Fezoui Y, Hartley DM, Harper JD, Khurana R, Walsh DM, Condron MM, Selkoe DJ, Lansbury PT, Fink AL, Teplow DB. An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments. Amyloid. 2000 Sep; 7(3):166-78. PMID: 11019857.
    Citations: 73     Fields:    Translation:HumansAnimalsCells
  56. Goldberg MS, Lansbury PT. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol. 2000 Jul; 2(7):E115-9. PMID: 10878819.
    Citations: 149     Fields:    Translation:HumansAnimals
  57. Conway KA, Harper JD, Lansbury PT. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry. 2000 Mar 14; 39(10):2552-63. PMID: 10704204.
    Citations: 247     Fields:    Translation:HumansCells
  58. Rochet JC, Lansbury PT. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol. 2000 Feb; 10(1):60-8. PMID: 10679462.
    Citations: 245     Fields:    Translation:HumansAnimalsCells
  59. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000 Jan 18; 97(2):571-6. PMID: 10639120; PMCID: PMC15371.
    Citations: 512     Fields:    Translation:HumansCells
  60. Lansbury PT, Kosik KS. Neurodegeneration: new clues on inclusions. Chem Biol. 2000 Jan; 7(1):R9-R12. PMID: 10662685.
    Citations: 3     Fields:    Translation:HumansCells
  61. Conway KA, Lee SJ, Rochet JC, Ding TT, Harper JD, Williamson RE, Lansbury PT. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann N Y Acad Sci. 2000; 920:42-5. PMID: 11193175.
    Citations: 79     Fields:    Translation:Humans
  62. Lansbury PT. Yeast prions: bungee cord domains' balancing act. Curr Biol. 1999 Nov 18; 9(22):R845-7. PMID: 10574755.
    Citations:    Fields:    Translation:HumansAnimalsCells
  63. Caughey B, Raymond GJ, Priola SA, Kocisko DA, Race RE, Bessen RA, Lansbury PT, Chesebro B. Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. An update. Mol Biotechnol. 1999 Nov; 13(1):45-55. PMID: 10934521.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  64. Koo EH, Lansbury PT, Kelly JW. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci U S A. 1999 Aug 31; 96(18):9989-90. PMID: 10468546; PMCID: PMC33726.
    Citations: 159     Fields:    Translation:Humans
  65. Zhen W, Han H, Anguiano M, Lemere CA, Cho CG, Lansbury PT. Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain. J Med Chem. 1999 Jul 29; 42(15):2805-15. PMID: 10425090.
    Citations: 11     Fields:    Translation:Humans
  66. Harper JD, Wong SS, Lieber CM, Lansbury PT. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry. 1999 Jul 13; 38(28):8972-80. PMID: 10413470.
    Citations: 116     Fields:    Translation:HumansCells
  67. Lansbury PT. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci U S A. 1999 Mar 30; 96(7):3342-4. PMID: 10097040; PMCID: PMC34271.
    Citations: 129     Fields:    Translation:HumansAnimalsCells
  68. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998 Nov; 4(11):1318-20. PMID: 9809558.
    Citations: 502     Fields:    Translation:HumansCells
  69. Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT, Kosik KS. A detergent-insoluble membrane compartment contains A beta in vivo. Nat Med. 1998 Jun; 4(6):730-4. PMID: 9623986.
    Citations: 115     Fields:    Translation:AnimalsCells
  70. Harper JD, Lieber CM, Lansbury PT. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem Biol. 1997 Dec; 4(12):951-9. PMID: 9427660.
    Citations: 125     Fields:    Translation:HumansCells
  71. Lansbury PT. Structural neurology: are seeds at the root of neuronal degeneration? Neuron. 1997 Dec; 19(6):1151-4. PMID: 9427238.
    Citations: 43     Fields:    Translation:HumansCells
  72. Lansbury PT. Yeast prions: inheritance by seeded protein polymerization? Curr Biol. 1997 Oct 01; 7(10):R617-9. PMID: 9368740.
    Citations:    Fields:    Translation:Animals
  73. Lansbury PT. Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease. Curr Opin Chem Biol. 1997 Aug; 1(2):260-7. PMID: 9667848.
    Citations: 9     Fields:    Translation:Humans
  74. Raymond GJ, Hope J, Kocisko DA, Priola SA, Raymond LD, Bossers A, Ironside J, Will RG, Chen SG, Petersen RB, Gambetti P, Rubenstein R, Smits MA, Lansbury PT, Caughey B. Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature. 1997 Jul 17; 388(6639):285-8. PMID: 9230438.
    Citations: 61     Fields:    Translation:HumansAnimalsCells
  75. Caughey B, Raymond GJ, Kocisko DA, Lansbury PT. Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. J Virol. 1997 May; 71(5):4107-10. PMID: 9094691; PMCID: PMC191566.
    Citations: 26     Fields:    Translation:AnimalsCells
  76. Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol. 1997 Feb; 4(2):119-25. PMID: 9190286.
    Citations: 189     Fields:    Translation:Humans
  77. Harper JD, Lansbury PT. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 1997; 66:385-407. PMID: 9242912.
    Citations: 430     Fields:    Translation:HumansAnimalsCells
  78. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 1996 Oct 29; 35(43):13709-15. PMID: 8901511.
    Citations: 512     Fields:    Translation:HumansCells
  79. Kocisko DA, Lansbury PT, Caughey B. Partial unfolding and refolding of scrapie-associated prion protein: evidence for a critical 16-kDa C-terminal domain. Biochemistry. 1996 Oct 15; 35(41):13434-42. PMID: 8873612.
    Citations: 36     Fields:    Translation:AnimalsCells
  80. Lansbury PT, Caughey B. The double life of the prion protein. Curr Biol. 1996 Aug 01; 6(8):914-6. PMID: 8805340.
    Citations: 3     Fields:    Translation:Animals
  81. Ashburn TT, Han H, McGuinness BF, Lansbury PT. Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides. Chem Biol. 1996 May; 3(5):351-8. PMID: 8807864.
    Citations: 13     Fields:    Translation:Cells
  82. Caughey B, Kocisko DA, Raymond GJ, Lansbury PT. Aggregates of scrapie-associated prion protein induce the cell-free conversion of protease-sensitive prion protein to the protease-resistant state. Chem Biol. 1995 Dec; 2(12):807-17. PMID: 8807814.
    Citations: 49     Fields:    Translation:AnimalsCells
  83. Lansbury PT, Costa PR, Griffiths JM, Simon EJ, Auger M, Halverson KJ, Kocisko DA, Hendsch ZS, Ashburn TT, Spencer RG, et al. Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat Struct Biol. 1995 Nov; 2(11):990-8. PMID: 7583673.
    Citations: 91     Fields:    Translation:HumansCells
  84. Bessen RA, Kocisko DA, Raymond GJ, Nandan S, Lansbury PT, Caughey B. Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature. 1995 Jun 22; 375(6533):698-700. PMID: 7791905.
    Citations: 159     Fields:    Translation:Animals
  85. Kocisko DA, Priola SA, Raymond GJ, Chesebro B, Lansbury PT, Caughey B. Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A. 1995 Apr 25; 92(9):3923-7. PMID: 7732006; PMCID: PMC42074.
    Citations: 94     Fields:    Translation:AnimalsCells
  86. Lansbury PT. Consequences of the molecular mechanism of amyloid formation for the understanding of the pathogenesis of Alzheimer's disease and the development of therapeutic strategies. Arzneimittelforschung. 1995 Mar; 45(3A):432-4. PMID: 7763339.
    Citations: 2     Fields:    Translation:Humans
  87. Han H, Weinreb PH, Lansbury PT. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem Biol. 1995 Mar; 2(3):163-9. PMID: 9383418.
    Citations: 84     Fields:    Translation:HumansCells
  88. Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A. 1995 Jan 31; 92(3):763-7. PMID: 7846048; PMCID: PMC42700.
    Citations: 74     Fields:    Translation:HumansCells
  89. Lansbury PT, Caughey B. The chemistry of scrapie infection: implications of the 'ice 9' metaphor. Chem Biol. 1995 Jan; 2(1):1-5. PMID: 9383397.
    Citations: 47     Fields:    Translation:HumansAnimals
  90. Lansbury PT. Mechanism of scrapie replication. Science. 1994 Sep 09; 265(5178):1510. PMID: 8079159.
    Citations: 8     Fields:    Translation:Cells
  91. Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, Lansbury PT, Caughey B. Cell-free formation of protease-resistant prion protein. Nature. 1994 Aug 11; 370(6489):471-4. PMID: 7913989.
    Citations: 233     Fields:    Translation:HumansAnimalsCells
  92. Jarrett JT, Berger EP, Lansbury PT. The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci. 1993 Sep 24; 695:144-8. PMID: 8239273.
    Citations: 81     Fields:    Translation:Humans
  93. Come JH, Fraser PE, Lansbury PT. A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc Natl Acad Sci U S A. 1993 Jul 01; 90(13):5959-63. PMID: 8327467; PMCID: PMC46846.
    Citations: 111     Fields:    Translation:HumansCells
  94. Jarrett JT, Lansbury PT. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993 Jun 18; 73(6):1055-8. PMID: 8513491.
    Citations: 567     Fields:    Translation:HumansAnimals
  95. Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993 May 11; 32(18):4693-7. PMID: 8490014.
    Citations: 511     Fields:    Translation:HumansCells
  96. Jarrett JT, Lansbury PT. Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB. Biochemistry. 1992 Dec 15; 31(49):12345-52. PMID: 1463722.
    Citations: 79     Fields:    Translation:Cells
  97. Lansbury PT. In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information. Biochemistry. 1992 Aug 04; 31(30):6865-70. PMID: 1637821.
    Citations: 25     Fields:    Translation:Cells
  98. Lellouch AC, Lansbury PT. A peptide model for the heparin binding site of antithrombin III. Biochemistry. 1992 Mar 03; 31(8):2279-85. PMID: 1540583.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  99. Spencer RG, Halverson KJ, Auger M, McDermott AE, Griffin RG, Lansbury PT. An unusual peptide conformation may precipitate amyloid formation in Alzheimer's disease: application of solid-state NMR to the determination of protein secondary structure. Biochemistry. 1991 Oct 29; 30(43):10382-7. PMID: 1931962.
    Citations: 14     Fields:    Translation:HumansCells
  100. Halverson K, Fraser PE, Kirschner DA, Lansbury PT. Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments. Biochemistry. 1990 Mar 20; 29(11):2639-44. PMID: 2346740.
    Citations: 63     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Lansbury's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (365)
Explore
_
Co-Authors (7)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.